 |
|
|
 |
VOLUME 34: NO. 3 MARCH 2007
Editorials
Education in Musculoskeletal Health — How Can It Be Improved to Meet Growing Needs?
Curriculum Design: Finding a Balance
Rheumatoid Arthritis and Diabetes Mellitus:
Evidence for an Association?
Is Minimal Clinically Important Difference
Relevant for the Interpretation of Clinical Trials in Pediatric Rheumatic Diseases?
Role of Thrombotic and Fibrinolytic Alterations
in the Pathogenesis and Treatment of
Osteonecrosis
Articles
Prevalent RA and Diabetes Among NHANES III Participants Aged 60 and Older
Infliximab Does Not Suppress the Tuberculin Skin Test (PPD)
Work Disability in RA — Development Over 15 Years and Evaluation of Predictive Factors Over Time
Hypothesis Adipose Tissue as a Modulator of
Clinical Inflammation: Does Obesity Reduce the Prevalence of RA?
Toll-like Receptor Expression in Lupus PBMC
Outcome Measurements in Scleroderma: Results from a Delphi Exercise
Safety and Efficacy of Readministration of
Infliximab After Longterm Continuous Therapy and Withdrawal in Patients with AS
Low Molecular Weight Phenotype of Apo(a) Is a Risk Factor of Corticosteroid-Induced Osteonecrosis of the Femoral Head After Renal Transplant
Adenoviral Gene Transfer of the Endogenous Inhibitor IkBa into Human OA Synovial Fibroblasts Demonstrates That Several MMP and Aggrecanases Are NF-kB-Dependent
A Model to Estimate HUI3 Utility Scores from WOMAC Index Scores in Patients with OA of the Knee
Tramadol for OA: A Systematic Review and Metaanalysis
Cyclic Compression Loaded on Cartilage Explants Enhances the Production of ROS
Evaluation of the Activity of an Academic Rheumatology Consult Service Over 10 Years:
Using Data to Shape Curriculum
Canadian Multidisciplinary Core Curriculum for Musculoskeletal Health
Pediatric Rheumatology
The Quality of My Life Questionnaire: The Minimal Clinically Important Difference for Pediatric Rheumatology Patients
Case Reports
Mycophenolate Mofetil and IV Dexamethasone
in the Treatment of Persistent Lupus Myelitis
Rapid Acetabular Osteolysis Secondary to Subchondral Insufficiency Fracture Images in Rheumatology
Joint Destruction in Septic Arthritis
OMERACT 8 International Consensus Conference on Outcome Measures in Rheumatology Clinical Trials, St. Julian's Bay, Malta, May 10-14, 2006
Introduction Biomarkers and Surrogate Endpoints
The WHO International Classification of Functioning, Disability and Health: A Conceptual Model and Interface for the OMERACT Process
Definitions and Validation Criteria for Biomarkers
and Surrogate Endpoints: Development and
Testing of a Quantitative Hierarchical Levels of Evidence Schema
Simulation Studies of Surrogate Endpoint Validation Using Single Trial and Multitrial Statistical Approaches
Synovial Macrophages as a Biomarker of
Response to Therapeutic Intervention in RA: Standardization and Consistency Across Centers
Testing of the Preliminary OMERACT Validation Criteria for a Biomarker to Be Regarded as
Reflecting Structural Damage Endpoints in RA Clinical Trials: The Example of CRP
Development of Draft Validation Criteria for a Soluble Biomarker to Be Regarded as a Valid Biomarker Reflecting Structural Damage Endpoints in RA and SpA Clinical Trials
Assessing Single Joints in Arthritis Clinical Trials
Letters
Sarcoid-like Granulomatous Disease Following Etanercept Treatment for RA
CRP in Primary Antiphospholipid Syndrome
Meetings in Rheumatology
|
